OM INTERACTIVE LTD

1. Financial Health Score: A (Excellent)

OM Interactive Ltd exhibits exceptional financial health, characterized by a robust balance sheet, strong liquidity, and zero long-term debt. The company has successfully grown its asset base over the past decade and maintains a very healthy cash position. The only minor concern is a relatively modest profit margin in the current year compared to its historical asset accumulation, but this is easily supported by its strong financial reserves.

2. Key Vital Signs

• Pulse Rate (Liquidity/Current Ratio): 2.54 – A strong and steady pulse. The company holds £2,000,910 in current assets against £787,414 in current liabilities, giving it more than enough working capital to meet its short-term debts without breaking a sweat.
• Blood Pressure (Debt Leverage): 100% Equity Funded for Long Term – Extremely healthy. The company shows no long-term creditors on the balance sheet. All liabilities are current (due within one year), meaning the business operates with virtually zero long-term financial strain.
• Red Blood Cell Count (Cash Reserves): £724,728 – Excellent oxygenation. Cash at bank has surged by nearly 68% from £430,410 in 2024, providing a massive financial cushion and the fuel needed for future growth or unexpected market shocks.
• Bone Density (Net Assets): £1,945,499 – Very strong skeletal structure. Net assets have grown steadily from £349,070 a decade ago to nearly £2 million today, demonstrating long-term structural resilience and value creation.
• Heartbeat (Profitability): £15,202 – Beating steadily, though quietly. The Profit and Loss reserve grew from £1,860,797 to £1,875,999. While positive, this represents a relatively modest profit for a company of this size and asset base.

3. Diagnosis

Overall Condition: Robust and Financially Immune to Short-Term Shocks

Looking under the microscope, OM Interactive Ltd is a financially robust patient. The business has built up substantial reserves over a long history (incorporated in 1997), and its balance sheet is structurally sound. The dramatic growth in net assets from 2016 to 2021 shows a business that was firing on all cylinders, rapidly accumulating wealth.

However, the financial blood work reveals some interesting physiological shifts in recent years: * Historical Recovery: In 2022, the company experienced a significant spike in liabilities (up to £1.5m from £693k the prior year), causing net assets to drop to £1.28m. This suggests a major event—perhaps a large loan or deferred income arrangement, or a significant expansion. The fact that the company has since cleared these long-term liabilities and rebuilt its net assets to £1.94m shows excellent recuperative power. * R&D Dependency: A significant portion of the company's fixed assets (£582,135 out of £732,003) is tied up in intangible assets (Research & Development). While entirely normal for a tech-focused sensory systems company, this represents a heavy reliance on intellectual property. The "amortisation" (write-down of these assets over their 5-year life) is a recurring expense that will suppress future profitability unless the R&D continues to generate commercial success. * Inventory Accumulation: Stocks remain high at £660,000. For a company with £2.7m in total assets, holding nearly a quarter of their value in stock could be a symptom of supply chain pre-buying or, potentially, slow-moving inventory that needs to be cleared.

4. Recommendations

To maintain peak financial wellness and optimize the body corporate, the following preventative and proactive measures are recommended:

1. Cash Deployment Strategy: With over £724k sitting in the bank, the company has more immediate liquidity than it strictly needs to operate. Consider whether this "resting heart rate" is too slow—could this cash be reinvested into higher-yield R&D, marketing, or new market expansion to drive faster growth? Alternatively, if the shareholders wish to realize some of this value, a dividend could be a healthy distribution.
2. Inventory Health Check: Conduct a thorough physical and financial review of the £660k in stock. Ensure that these are not "fatty deposits" of obsolete or slow-moving sensory equipment. Efficient stock turnover will improve overall cash flow efficiency.
3. Monitor the R&D Pipeline: With heavy capitalization in intangible assets, it is vital that the R&D pipeline continues to produce commercially viable products. Ensure that the 5-year amortization schedule aligns with the actual commercial lifespan of the products being developed, so the balance sheet doesn't suffer sudden impairments.
4. Profitability Focus: While the balance sheet is incredibly healthy, the modest £15k bottom-line profit suggests that operating margins might be tight. Management should review cost structures to ensure that the immense value built up in the company's reserves is reflected in annual profit generation.